Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: MDT.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Medtronic (MDT) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$102

+10.6%+13.1% incl. dividends

2031

5-Year

BUY

$145

+56.9%+75.8% incl. dividends

Published batch insight

Accelerating Clinical Moats Drive Cash Compounding Beyond Bureaucratic Stagnation

High consensus confirms underlying organic growth has inflected toward 7%, driven by pulsed field ablation dominance and non-cyclical demographic demand. Valuation re-rating faces sharp divergence, as 5% Treasury yields, hospital capital rationing, and electrophysiology price wars cap multiple expansion.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Michael Burry (Vulture), Elon Musk (Visionary), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), J.P. Morgan (Titan), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Medtronic at the forecast anchor (2026-09-18): $17,580 in five years versus $13,892 for S&P 500 benchmark.

Medtronic · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.3% net dividend yield for Medtronic.

Figure: Five-year synthesized consensus value path for Medtronic compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 92.13 USD1-year price return: +10.58%5-year price return: +56.91%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	94.40	+2.47%	+2.47%	The MiniMed split-off exchange offer concludes, retiring roughly 4% of parent shares. Sustained double-digit electrophysiology volume growth counters elevated Treasury yields, allowing per-share cash accretion to produce a measured initial valuation advance.
Q1 2027	97.01	+2.76%	+5.30%	Third-quarter results demonstrate underlying organic demand holding near 7% after stripping out calendar distortions. Expanding commercial coverage for renal denervation procedures and steady cardiac pacing replacements reinforce confidence, prompting steady institutional accumulation.
Q2 2027	99.50	+2.56%	+7.99%	Fiscal 2027 closes with solid earnings, but forward fiscal 2028 guidance reveals optical revenue contraction from diabetes deconsolidation. Resilient consumable cash flows prevent severe drawdowns, though headline-driven allocator caution temporarily caps quarterly performance.
Q3 2027	101.87	+2.39%	+10.58%	Initial post-split reporting clarifies underlying operating margin expansion and higher revenue quality. Sustained international Affera catheter pull-through dispels deceleration fears, prompting sell-side margin upgrades and renewed upward valuation momentum.
Q4 2027	104.84	+2.91%	+13.80%	Manufacturing efficiency gains and cleanroom automation begin lowering unit production costs across cardiovascular product lines. High-margin disposable catheter utilization accelerates, translating volume growth into positive operating leverage and steady equity gains.
Q1 2028	106.54	+1.62%	+15.64%	Hospital capital budget tightening and seasonal respiratory pressures temporarily moderate large-scale equipment installations. However, non-deferrable chronic implant procedures cushion cash flow, keeping equity pricing resilient despite selective competitive discounting in electrophysiology.
Q2 2028	110.05	+3.30%	+19.45%	Full-year fiscal 2028 earnings validate structural operating margins exceeding 18.5%. Cash generation comfortably funds the 51st consecutive annual dividend increase, attracting defensive institutional capital seeking dependable yields amid late-cycle macroeconomic deceleration.
Q3 2028	112.20	+1.95%	+21.78%	Spine navigation integration and cranial technology suites drive steady surgical implant cross-selling. Incremental procedural adoption offsets Section 301 component tariff friction, supporting stable earnings visibility and moderate share price compounding.
Q4 2028	115.11	+2.59%	+24.94%	Outpatient renal denervation adoption broadens across commercial payers, scaling cath-lab procedure volumes. Favorable therapeutic mix and maturing manufacturing lines lift free cash flow conversion, reinforcing market perception of genuine operational turnaround.
Q1 2029	117.25	+1.87%	+27.27%	Rival medtech entries in pulsed field ablation trigger competitive pricing friction across European accounts. Procedure volumes continue expanding, but narrower catheter average selling prices moderate incremental operating leverage, leading to modest consolidation.
Q2 2029	119.86	+2.22%	+30.09%	Fiscal 2029 results highlight robust trailing free cash flow exceeding $6.8 billion. Operating expense discipline successfully absorbs international volume-based procurement cuts, enabling opportunistic anti-dilutive share repurchases that support per-share intrinsic value.
Q3 2029	122.05	+1.83%	+32.47%	Scheduled manufacturing facility consolidations and plant rationalizations generate permanent structural cost savings. Non-cyclical demographic demand for structural heart implants buffers broader economic weakness, ensuring dependable defensive financial performance.
Q4 2029	125.43	+2.77%	+36.15%	Second-generation pulsed field ablation catheters and navigation software integrations launch globally. Enhanced clinician retention and recurring consumable reorders re-accelerate cardiovascular margins, driving positive institutional sentiment and solid quarterly appreciation.
Q1 2030	127.62	+1.74%	+38.52%	Higher-for-longer sovereign interest rates continue capping valuation multiple expansion across large-cap medtech. Nevertheless, disciplined working capital management and steady neurostimulation replacement cycles ensure resilient cash compounding without balance-sheet strain.
Q2 2030	130.76	+2.47%	+41.93%	Fiscal 2030 financial disclosures demonstrate adjusted operating margins approaching 20% on the optimized post-separation portfolio. Strong free cash flow conversion reinforces dividend aristocrat positioning, underpinning durable mid-single-digit shareholder returns.
Q3 2030	133.19	+1.86%	+44.57%	Seasonal summer surgical moderation slightly tempers quarterly revenue velocity. Established enterprise hospital bundling contracts and steady cardiac pacing implants protect baseline operating profits, preserving recent valuation gains.
Q4 2030	136.39	+2.40%	+48.04%	Matured renal denervation and robotic surgical instrumentation cohorts deliver consistent, high-margin consumable annuities. Broadening international procedures cushion domestic pricing scrutiny, sustaining steady per-share cash flow expansion and upward price tracking.
Q1 2031	138.53	+1.57%	+50.37%	Pricing pressures in standardized vascular commodities are fully mitigated by high-volume transcatheter aortic valve deployments. Investors value the franchise as an essential healthcare compounder, supporting share prices through steady operational execution.
Q2 2031	141.94	+2.46%	+54.06%	Fiscal 2031 results mark the completion of a five-year turnaround, with annual free cash flow approaching $7.5 billion. Expanding owner earnings and disciplined balance sheet deleveraging validate the long-term margin recovery thesis.
Q3 2031	144.56	+1.85%	+56.91%	The forecast horizon closes with valuation anchored by durable cash compounding and disciplined share count reduction. Structural procedure growth across an aging global population secures steady terminal cash generation.

Medtronic's core investment thesis represents an operational transition from conglomerate stagnation to high-margin cash compounding. Underlying organic top-line velocity has inflected to approximately 7%, once adjusted for the 53-week fiscal distortion, propelled by rapid adoption of Affera Sphere-9 pulsed field ablation, Evolut FX+ valves, and renal denervation. The strategic separation of the capital-intensive MiniMed diabetes unit retires approximately 4% to 5% of outstanding equity while structurally eliminating margin-dilutive overhead. Crucially, trailing free cash flow of $6.13 billion establishes a 5.2% cash yield that fully underwrites progressive dividend commitments and internal R&D. Valuation sensitivity remains acutely anchored to the sovereign macro backdrop. With benchmark 10-year Treasury yields near 5%, equity discount rates harshly penalize long-duration cash flows, preventing a return to historical peak multiples above 25 times earnings. Furthermore, aggressive commercial counterattacks from incumbent peers will inevitably erode electrophysiology catheter pricing power. Consequently, shareholder value must be generated primarily through earnings compounding, operational leverage from manufacturing footprint consolidation, and share retirement rather than speculative multiple expansion.

Key insights

Pulsed field ablation shifts electrophysiology revenue from cyclical equipment sales to high-margin recurring catheter pull-through, systematically expanding cardiovascular gross margins.
MiniMed's tax-free split-off functions as a discounted share repurchase, permanently lifting per-share intrinsic owner earnings without deploying liquid balance-sheet reserves.
Restrictive sovereign borrowing costs constrain hospital capital budgets, enforcing flexible robotic leasing models and shifting economic returns onto single-use consumables.

Deep Dive

Prevailing market consensus treats the enterprise as a lumbering, low-beta dividend utility trapped in historical 3% to 4% organic growth. Investors anchor on past execution slips, hospital capital equipment freezes, and headline calendar distortions, viewing recent revenue acceleration as a transitory artifact. Consequently, the crowd prices the business at an undemanding multiple, heavily discounting management's margin turnaround narrative and treating competitive share erosion as permanent.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value due to an analytical blind spot regarding underlying operational momentum. Consensus mistakenly dismisses Q1 fiscal 2027 performance as mere calendar noise, overlooking that organic growth reached 7% led by an 88% surge in cardiac ablation. Furthermore, the market fails to price the EPS accretion of retiring 4% to 5% of parent equity via the MiniMed split-off. This disconnect offers an attractive margin of safety anchored by a 5.2% free cash flow yield.

Repricing catalyst

Completion of the MiniMed share exchange offer in late 2026, followed by consecutive ordinary-length quarterly prints confirming sustained 6.5%+ organic top-line growth, will close the gap. As reported operating margins approach 19% without diabetes dilution, sell-side analysts will be forced to lift forward earnings estimates throughout fiscal 2027 and 2028, compelling institutional rotation into the shares.

Published consensus context

Macro regime alignment

The macroeconomic backdrop represents a mixed setup. Benchmark 10-year Treasury yields near 5% and restrictive central bank policy impose duration-driven multiple compression and lengthen hospital capital equipment sales cycles. However, non-discretionary clinical procedural demand exhibits near-total economic inelasticity, insulating surgical implant volumes, cash collection, and debt service from consumer slowdowns.

Published consensus context

Advisor disagreement

The decisive disagreement across reports centers on terminal valuation multiples and operational execution speed. Growth-oriented views argue that pipeline breakthroughs in pulsed field ablation and robotics justify aggressive multiple expansion toward 20 to 24 times earnings. Conversely, skeptical frameworks insist that 5% benchmark bond yields, hospital capital freezes, and bureaucratic inertia will cap multiples near 15 to 16 times, limiting appreciation strictly to organic cash flow compounding. Resolving this tension requires tracking ordinary-length quarterly organic growth without calendar distortions and monitoring electrophysiology gross margins against competitive pricing pressure.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Pulsed field ablation portfolio scale: Commercial adoption of the Affera mapping system and PulseSelect catheter is transforming electrophysiology, delivering 88% growth in cardiac ablation. This technology converts installations into recurring, high-margin consumable catheter revenue. Installed-base expansion captures procedure share from thermal ablation, driving sustained cardiovascular margin accretion and lifting earnings over the five-year forecast horizon. Expected impact: +20%.
Inelastic demographic surgical demand: Aging global demographics generate non-discretionary procedural volume for transcatheter aortic valves, leadless pacemakers, and neurostimulation devices. Non-deferrable chronic disease interventions insulate Medtronic from cyclical economic downturns. This biological volume momentum underpins reliable mid-single-digit organic top-line expansion and defensive operational cash generation exceeding $6 billion annually. Expected impact: +14%.
MiniMed split-off per-share accretion: Separating the capital-intensive diabetes unit via an equity exchange offer retires an estimated 4% to 5% of outstanding parent shares at a discount. This portfolio pruning eliminates margin-dilutive hardware manufacturing, reduces dividend payout liabilities, and sharpens return on invested capital, immediately lifting structural earnings per share. Expected impact: +13%.
Manufacturing rationalization and operating leverage: Aggressive supply-chain consolidation, plant footprint rationalization, and automated cleanroom manufacturing are reversing post-pandemic cost bloat. Operating margins stabilized at 17.8% and possess a viable path toward 20% as commercial launches mature. Cost absorption allows incremental revenue to flow directly into expanding free cash flow per share. Expected impact: +11%.

Top frictions and headwinds

Restrictive sovereign yield multiple ceiling: Benchmark 10-year Treasury yields hovering near 5% and central bank policy rates around 4% exert relentless downward gravity on equity valuation multiples. High risk-free yields make Medtronic's 3% dividend yield and 5.2% cash yield relatively less compelling, strictly capping multiple expansion and forcing total returns to rely entirely on earnings growth. Expected impact: -9%.
Hospital capital budget tightening headwinds: Elevated borrowing costs and tight healthcare operating margins force hospital procurement committees to ration capital expenditure. Healthcare networks defer large purchases of Hugo surgical robotic towers and advanced imaging consoles. This institutional capital rationing lengthens sales cycles, compressing upfront capital equipment revenue and slowing high-margin instrument utilization. Expected impact: -8%.
Intense electrophysiology competitive pricing warfare: Well-capitalized peers, notably Boston Scientific and Abbott, are defending cath-lab market share through aggressive pricing and bundled contracts. As pulsed field ablation catheters proliferate, hospital purchasing consortiums demand deeper discounts. This rivalry forces elevated marketing expenses, compressing catheter average selling prices and limiting incremental gross profit expansion. Expected impact: -7%.
Global procurement price compression: Expanding centralized volume-based procurement across China and mandatory budgetary reimbursement caps in European single-payer systems enforce statutory price cuts on mature devices. These administrative price reductions inflict steady headwinds on mature cardiac pacing and spinal hardware lines, offsetting premium pricing gains achieved in advanced therapeutic categories. Expected impact: -7%.

Tail risks

Flagship implant Class I safety recall: A systemic hardware defect, dielectric breakdown, or battery failure across core pulsed field ablation or leadless pacemaker lines triggering an FDA Class I recall would be devastating. Beyond remediation expenses exceeding $1 billion, procedural halts and clinician defections to rival platforms would permanently impair cardiovascular earnings power. Probability: +21%. Expected impact: -22%.
Sovereign healthcare mandatory payment reset: Severe fiscal deficits forcing US legislative expansion of mandatory reimbursement price cuts across inpatient physician-preference implantable devices would crush hospital economics. Forcing statutory discounts on pacemakers, valves, and neuromodulation hardware would compress gross margins below 60%, precipitating earnings contractions and multiple de-rating across medtech. Probability: +24%. Expected impact: -17%.

Tail opportunities

Renal denervation reimbursement floodgate opening: CMS establishing broad, permanent outpatient reimbursement alongside synchronized private payer coverage for Symplicity Spyral by 2028 would unlock a multi-billion-dollar market. Treating millions of uncontrolled hypertensive patients would accelerate corporate organic revenue growth above 8%, generating high-margin catheter cash flows and driving multiple expansion. Probability: +34%. Expected impact: +21%.
Hugo robotic multi-specialty FDA clearance: Securing unencumbered FDA 510(k) clearances for the Hugo robotic system in high-volume general surgery and gynecology before 2028 would break Intuitive Surgical's near-monopoly. Capturing substantial soft-tissue procedure volume would drive high-margin recurring instrument and stapler pull-through, lifting operating margins beyond 21% and boosting valuation. Probability: +29%. Expected impact: +18%.

What to monitor

Thesis watchpoints

-- Retained-business organic revenue growth maintains at least 6.5% over two consecutive normal-length quarters through fiscal 2028.

Key insights

Consolidated adjusted gross margin contracting below 64.0% over two consecutive quarters signals unabsorbed tariff friction or price wars.
Failure to complete the MiniMed share exchange offer or major FDA regulatory suspensions on Affera require thesis reset.

Company Financial Analysis

Medtronic Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Medtronic's financial results demonstrate an unmistakable shift from multi-year stagnation toward authentic operational acceleration. For fiscal 2026, reported revenue expanded 8.4% to $36.4 billion, and the momentum continued into the first quarter of fiscal 2027 with reported organic growth of 13.7%. While an extra selling week flattered that headline figure, underlying growth remained solid at roughly 7%, spearheaded by an extraordinary 88% surge in cardiac ablation solutions. Crucially, this top-line resurgence is backed by genuine cash generation rather than accounting gimmicks. Trailing free cash flow reached $6.13 billion, comfortably funding $3.64 billion in annual dividend payments while supporting disciplined share buybacks. As high-margin procedural consumables outpace capital equipment sales, earnings quality is steadily improving across core divisions.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2026	USD 36.4B	USD 4.8B	USD 5.4B
2025	USD 33.5B	USD 4.7B	USD 5.2B
2024	USD 32.4B	USD 3.7B	USD 5.2B
2023	USD 31.2B	USD 3.8B	USD 4.6B
2022	USD 31.7B	USD 5B	USD 6B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2026	21.7x	TTM	Native	USD / USD
2025	23.4x	TTM	Native	USD / USD
2024	28.1x	TTM	Native	USD / USD
2023	32.2x	Annual	Native	USD / USD
2022	27.6x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability margins are establishing a durable floor after absorbing years of post-pandemic supply-chain inflation and tariff expenses. Gross margin held steady at 65.0% in fiscal 2026, while operating margin improved to 17.8%. In the first quarter of fiscal 2027, net income jumped 41% as manufacturing efficiencies and favorable procedural mix took hold. This margin recovery reflects structural improvements rather than temporary cost-cutting. Premium pulsed field ablation catheters command higher profitability than older thermal tools, while shedding the lower-margin diabetes division will immediately lift consolidated margins. As automated factory production expands, operating margins possess a clear pathway toward 20% over the next several years.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2026	USD 6.5B	17.8%	13.2%
2025	USD 6B	17.8%	13.9%
2024	USD 5.1B	15.9%	11.4%
2023	USD 5.5B	17.6%	12.0%
2022	USD 5.8B	18.2%	15.9%

Balance sheet and leverage

AI Review

Medtronic operates from a conservative financial position designed to navigate restrictive interest rate environments smoothly. The company closed fiscal 2026 with $93.0 billion in total assets against $49.5 billion in shareholder equity, resulting in a prudent debt-to-equity ratio of 0.57. Manageable debt servicing is underscored by an interest coverage ratio of 9.6 times. While gross debt stands near $28 billion and historical acquisitions leave substantial intangible assets on the books, robust operating liquidity and a current ratio of 2.13 provide substantial protection. Generating over $6 billion in annual free cash flow ensures Medtronic can easily service its obligations and sustain dividend increases without needing external borrowing.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2026	USD 28B	USD 9.2B	USD 26B net debt	2.13x
2025	USD 28.5B	USD 9B	USD 26.3B net debt	1.85x
2024	USD 25B	USD 8B	USD 23.7B net debt	2.03x
2023	USD 24.4B	USD 8B	USD 22.8B net debt	2.39x
2022	USD 24.1B	USD 10.6B	USD 20.4B net debt	1.86x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management is exercising tight capital discipline, maintaining capital expenditures at a modest 5.2% of revenue while directing $2.87 billion annually into targeted research and development. Rather than chasing expensive, dilutive mega-acquisitions, capital is deliberately focused on automated cleanrooms, precision tooling, and clinical regulatory trials for high-margin catheters and robotics. The most decisive capital allocation move is subtractive: spinning off the capital-intensive diabetes unit. Exiting pump manufacturing eliminates a business with high research requirements, freeing up financial resources for cardiac ablation and soft-tissue surgery. This selective reinvestment posture optimizes returns on invested capital and preserves strong cash conversion.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2026	USD 1.9B	USD 2.9B
2025	USD 1.9B	USD 2.7B
2024	USD 1.6B	USD 2.7B
2023	USD 1.5B	USD 2.7B
2022	USD 1.4B	USD 2.7B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	258	+13.9%	Not available	ORIGINAL
5Y	BUY	228	+79.6%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	90.29	94.63	96.74	14
+6M	March 18, 2027	93.9	97.27	100.61	14
+9M	June 18, 2027	93.89	100.34	106.64	14
+1Y	September 18, 2027	95.84	102.63	109.84	14
+15M	December 18, 2027	97.76	105.65	114.24	14
+18M	March 18, 2028	98.74	107.55	116.52	14
+21M	June 18, 2028	101.7	111.18	122.35	14
+2Y	September 18, 2028	101.7	113.43	126.02	14
+27M	December 18, 2028	103.73	116.36	131.06	14
+30M	March 18, 2029	101.66	118.66	133.68	14
+33M	June 18, 2029	103.69	121.87	140.36	14
+3Y	September 18, 2029	104.73	124.27	144.57	14
+39M	December 18, 2029	106.82	127.65	148.91	14
+42M	March 18, 2030	106.82	129.87	151.89	14
+45M	June 18, 2030	108.96	133.39	157.96	14
+4Y	September 18, 2030	110.05	135.89	162.7	14
+51M	December 18, 2030	111.15	139.15	167.58	14
+54M	March 18, 2031	111.15	141.39	170.94	14
+57M	June 18, 2031	113.37	145.1	177.77	14
+5Y	September 18, 2031	114.51	147.87	183.11	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus reveals an operational inflection in underlying organic revenue growth toward 6% to 7%, led by rapid pulsed field ablation adoption and resilient non-cyclical procedural demand. Multiple reports correlate by projecting substantial valuation re-rating; however, rigorous scrutiny proves multiple expansion is severely constrained by benchmark sovereign bond yields hovering near 5% and persistent tariff frictions. Heaviest weighting is awarded to analyses grounded in primary SEC filings, which correctly adjust Q1 fiscal 2027 performance for the 53-week calendar effect and model the MiniMed split-off as a share-count retirement rather than free cash infusion. Credible contrarian reasoning identifying hospital capital budget rationing, slow surgical robotics adoption, and inevitable electrophysiology catheter price erosion is preserved to counterbalance aggressive growth forecasts. Unsupported claims of dramatic multiple expansion toward historical zero-rate peaks are downweighted, grounding the consensus in cash-flow compounding and margin recovery.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight13.3/100

Exemplary primary evidentiary grounding across regulatory filings and exchange offer mechanics. It correctly deconsolidates diabetes revenue, isolates the 53-week calendar effect, and rigorously articulates how tariff friction and sovereign yields cap multiple expansion while earnings compound.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight11.4/100

This analysis provides rigorous primary source verification across SEC filings and clinical notices. It properly adjusts reported Q1 growth for the extra selling week and treats MiniMed separation economics realistically. Its valuation cross-check against benchmark bond yields anchors prudent baseline compounding.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight7.6/100

Presents strong macroeconomic causal framing contrasting late-cycle sovereign debt yields with inelastic procedural demand. The rationale incisively details per-share accretion from the MiniMed exchange offer, though it slightly downplays persistent competitive pricing pushback in electrophysiology.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight7.6/100

Delivers an essential contrarian critique highlighting corporate bureaucratic inertia, surgical robotics commercialization lag, and hospital capex impasses. While its organic growth forecast of 5.5% is excessively punitive, its skepticism on multiple expansion provides a vital ballast.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.7/100

Sound long-term owner orientation focused on durable procedural moats and free cash flow generation. However, it lacks primary research source citations and models multiple expansion too optimistically despite acknowledging hospital capital budget rationing headwinds.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.7/100

Offers solid reasoning regarding supply-chain rationalization and manufacturing leverage. Nevertheless, it accepts headline revenue acceleration without adjusting for calendar distortions and unconvincingly assumes multiple re-rating to 25 times earnings in a restrictive interest rate environment.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight6.7/100

Accurately maps the clinical reimbursement opportunity for renal denervation alongside solid balance sheet metrics. It lacks specific SEC source citations and treats the diabetes separation merely as an upside tail option rather than an ongoing corporate action.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight6.7/100

Provides sharp forensic insights into plant rationalization, footprint exits, and activist governance influence on margins. It models steep multiple re-rating without thoroughly accounting for electrophysiology catheter average selling price erosion from competing platforms.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight6.7/100

Accurately normalizes Q1 organic top-line velocity and highlights capital-light console placement dynamics. However, it relies heavily on unmodeled forward multiple re-rating and overlooks transition service liabilities following the diabetes unit separation.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.7/100

Strong analysis of institutional coding durability and regulatory capture via CMS renal denervation determinations. However, it assumes an aggressive multiple re-rating to 20 times forward earnings that conflicts with broader sovereign yield pressures.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight5.7/100

Accurately identifies non-cyclical biological procedural demand as a shield against macroeconomic stagflation. It overstates diabetes hardware retention benefits by failing to recognize the near-term completion of the MiniMed split-off exchange offer.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight5.7/100

Good synthesis of fixed-cost operational leverage and structural heart franchise stability. Yet it misses the specific structural mechanics of the share retirement in the pending split-off, treating portfolio separation more loosely than primary documentation warrants.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight4.8/100

Presents an aggressive growth thesis emphasizing hospital procurement lock-in. However, the path relies on heroic multiple expansion to 19 times and doubling enterprise value, largely dismissing serious competitive counter-offensives and ongoing product liability litigation risks.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.8/100

Constructs an insightful narrative around clinical software integration into cath-lab hardware. However, the projected 98% five-year equity price trajectory is fundamentally disconnected from disciplined cash-flow discounting in an elevated sovereign yield regime.

Skip to references

Research Provenance

References & Context

This Medtronic consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 37 deduplicated sources retained for this batch.

01Renal Denervation for Uncontrolled Hypertension | CMScms.gov
02Documentsec.gov
03mdt-20260424sec.gov
04Medtronic plc - Form 10-Q - FY2026sec.gov
05Medtronic plc - Form 8-K - FY2026sec.gov
06Medtronic plc - Form 8-K - FY2026sec.gov
07www.sec.govsec.gov
08https://assets.hpra.ie/data/docs/default-source/product-updates/fsn/field-safety-notices/march-2026/sphere-9-catheter_medtronic-inc-_advice-regarding-changes-or-updates-made-to-instructions-for-use.pdf?sfvrsn=e2ba80ec_3assets.hpra.ie
09Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - BioSpacebiospace.com
10Medtronic Diabetes to submit patch pump to FDA by fall 2026drugdeliverybusiness.com
11Medtronic PLC (MDT) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and Raised ...finance.yahoo.com
12Medtronic launches exchange offer to split off MiniMed stake - Financial Newsfinancial-news.co.uk
13Medtronic (MDT) to Announce Q1 FY2027 Earnings on August 18gurufocus.com
14Medtronic Diabetes Business Separation - iData Researchidataresearch.com
15Earnings call transcript: Medtronic beats Q1 2026 estimates and lifts outlook By Investing.cominvesting.com

And 22 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2015-04-30–2026-04-30, 12 periods; quarterly: 2023-10-31–2026-07-31, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.